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NK cells are appreciated as antitumour effector cells in
mouse models and human hematologic malignancies
but their relevance in immunosurveillance of human
solid tumours remains conflicting due to problems with
in situ detection and reports of functional inactivity in
the tumour milieu. The study was performed to identify
mechanisms that impair NK-cell function in the tumour
milieu and thereby identify therapeutic targets that
allow recovery of NK-cell functionality.
We used in situ detection and flow cytometry to localise,
quantify and profile NK cells of human clear cell renal cell
carcinoma (ccRCC) tissue. Strategies were evaluated to
reinstate functionality of tumour-derived NK cells. In vitro
coculture models were applied to gain mechanistic insight
into tumour-induced NK-cell alterations.
Tumour-resident NK cells, compared to NK cells from
non-tumour kidney and PBLs, displayed conjoint pheno-
typic alterations and dysfunction induced by the tumour
milieu, which were associated mechanistically with high
levels of signaling attenuator diacylglycerol kinase
(DGK)-a and blunted mitogen-activated protein kinase
pathway activation (ERK1/2, JNK). Reinstating NK-cell
functionality was possible by DGK-inhibition or brief
IL-2-culture, interventions that de-repressed the ERK
pathway. The extent of alteration and magnitude of recov-
ery could be linked to NK-cell frequency within ccRCC-
infiltrating lymphocytes, possibly explaining the observed
survival benefit of patients with NKhigh tumours.
DGK-mediated dampening of the ERK pathway ensu-
ing in NK-cell dysfunction was identified as an impor-
tant escape mechanism in ccRCC. DGK and the ERK
pathway emerge as promising therapeutic targets to
restore suppressed NK-cell activity for the improvement
of antitumour immunity.
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